Drug Profile
Research programme: nucleoside inhibitors - Gilead Sciences
Alternative Names: 4'-substituted 2'd2'F nucleoside analogues - Gilead; 4'-substituted β-d-2'-deoxy-2'-α-fluoro nucleoside inhibitors - GileadLatest Information Update: 24 Jul 2023
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Class Antivirals
- Mechanism of Action Polymerase inhibitors; Viral RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Respiratory syncytial virus infections
Most Recent Events
- 24 Jul 2023 Discontinued - Preclinical for Respiratory syncytial virus infections in USA (unspecified route)
- 28 May 2019 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections in USA
- 29 Apr 2015 Preclinical trials in Respiratory syncytial virus infections in USA (unspecified route)